AGA Updates Barrett's Guidelines + GLP-1 Safety Study | Oct 28

Welcome to this week's Gastroenterology and Endoscopy News Roundup, where we bring you the most important updates and research findings for gastroenterology professionals. This episode covers five critical stories from the week of October 21-28, 2025, including new clinical guidelines, groundbreaking research on procedure safety, and the latest technological innovations in endoscopy.1. AGA Releases Updated Barrett's Esophagus Surveillance GuidelineThe American Gastroenterological Association has published a significant update to its clinical practice guideline on Barrett's esophagus surveillance. The new guideline represents a paradigm shift from uniform monitoring to a risk-based, individualized approach.Clinical Impact: This guideline helps optimize resource allocation while improving early detection of neoplasia in higher-risk patients.2. OCULUS Trial: Holding GLP-1 Agonists Before Endoscopy Reduces RiskThe OCULUS randomized controlled trial, presented at ACG 2025, provides the first RCT evidence on managing GLP-1/GIP-1 receptor agonists before upper endoscopy.Clinical Impact: Strong evidence for holding these increasingly common medications before elective upper endoscopy to ensure patient safety and reduce aspiration risk.3. Landmark Study Reveals 22% of Esophageal Cancers Missed on EndoscopyA large population-based study from Finland and Sweden analyzed over 15,000 Barrett's esophagus patients and uncovered concerning rates of post-endoscopy esophagogastric cancers (PEEC).Clinical Impact: Highlights urgent need for quality metrics in upper endoscopy, similar to adenoma detection rates in colonoscopy, to reduce missed cancers.4. Fujifilm Launches ELUXEO 8000 Endoscopic Imaging SystemFUJIFILM Healthcare Americas has unveiled its next-generation endoscopy platform with enhanced imaging capabilities.Clinical Impact: Backward compatibility offers practical upgrade path for existing users while enhancing diagnostic and therapeutic capabilities.5. FDA Approves Once-Monthly Omvoh Injection for Ulcerative ColitisThe FDA has approved a more convenient maintenance regimen for Eli Lilly's mirikizumab-mrkz (Omvoh) for moderately to severely active ulcerative colitis.Clinical Impact: Simplified treatment regimen may improve patient adherence and reduce injection burden.SponsorThis episode is sponsored by DigestiveJobs.comDigestiveJobs.com is the leading career resource for gastroenterology and endoscopy professionals. Whether you're seeking new opportunities, looking to hire talented clinicians, or exploring career advancement, DigestiveJobs.com connects you with the best positions and candidates in the field.Visit DigestiveJobs.com to explore current opportunities and advance your career in gastroenterology.https://www.gastroendopod.com

In this episode, we cover five crucial updates shaping gastroenterology and endoscopy practice in 2025. From the practice-changing ENDURO trial comparing endoscopic to surgical approaches for malignant gastric outlet obstruction, to the latest EASL hepatitis B management guidelines, AI applications in endoscopy, sedation innovations, and biomarker-driven approaches to IBS.Resources & LinksENDURO Trial & EUS-Guided GastroenterostomyENDURO Study Protocol - Trials JournalENDURO Trial Results - The Lancet Gastroenterology & HepatologyEUS-GE Overview - Gastroenterology & Endoscopy NewsProspective Study - Gastrointestinal EndoscopyEASL 2025 Hepatitis B GuidelinesEASL HBV Guidelines 2025 - Journal of HepatologyEASL Guidelines Summary - EASL WebsiteHBV Guidelines PDF - Hepatitis B FoundationAI in EndoscopyAI and Polyp Detection Review - PMCAI-Assisted Colonoscopy Meta-Analysis - Annals of Internal MedicineUse of AI in Colonoscopy - Gastrointestinal EndoscopyEndoscopist Deskilling Study - The LancetBibliometric Analysis - Frontiers in MedicineSedation InnovationsRemimazolam Review - Clinical EndoscopyRemimazolam vs Propofol Meta-Analysis - British Journal of AnaesthesiaRemimazolam Comprehensive Review - World Journal of GI EndoscopyRemimazolam Real-World Study - BMC GastroenterologySafety and Efficacy Comparison - BMC AnesthesiologyIBS Biomarkers & Microbiome2025 Seoul Consensus on IBS - PMC16S rRNA Microbiome Biomarkers for IBS - PMCInternational Consensus on Microbiome Testing - Gut Microbiota for HealthGut Microbiome Resilience Review - Frontiers in MicrobiologyThis podcast is for educational purposes only and does not constitute medical advice. Always consult current guidelines and use clinical judgment when making treatment decisions.https://www.gastroendopod.com

In this quick-hit episode, we cover the freshest guidelines reshaping IBD, colorectal surveillance, gastric premalignancy, and gastroparesis management. Dive into cutting-edge research on AI for efficiency, targeted therapies, H. pylori strategies, advanced endoscopy, and cost-saving insights. Plus, spotlight on new tech warnings, bariatric devices, GERD diagnostics, and the game-changing FDA approval for subcutaneous Tremfya in UC. Perfect for busy GI pros—actionable takeaways to level up your practice.Key Segments and Highlights:Guidelines Rundown:BSG on IBD: Enhanced primary care pathways, CRC risk stratification, and patient adherence strategies to reduce post-colonoscopy cancers.ACG on Gastric Premalignancy: First-ever guidance on atrophic gastritis, GIM, dysplasia—focus on H. pylori eradication and tailored surveillance.BSG on Colorectal Surveillance: Clear start/stop criteria post-polypectomy and in IBD, with tips for better patient buy-in.AGA on Gastroparesis: 12 recs for diagnosis (scintigraphy) and treatments (prokinetics, G-POEM)—emphasizing personalized, multidisciplinary care.Rome/International on Gastroparesis: Aligns with AGA, adds psychosocial screening and global non-pharma standards. Takeaway: Download from AGA/ACG/BSG sites and audit your protocols.Research Pulse:AI in Guideline Development (AGA Pilot): Cuts review time/costs dramatically for Crohn's biologics—use with human validation.Targeted Drug Delivery: Nanoparticles for IBD/motility; watch for retention improvements.H. pylori in MI Patients (ESC Data): Selective screening for high-risk antiplatelet users to curb GI bleeds.EUS-Guided Gastroenterostomy: Standardization boosts success >90%; includes troubleshooting videos.ASIDE Gastroenterology New Issue: Covers MMF in IBD, tofacitinib in peds UC, ESD aids, gastric cancer immunotherapy, and more.Optical Enhancement Endoscopy RCT: 92% sensitivity for gastric metaplasia/neoplasia—upgrade for high-risk screens.Hospital Affiliation Costs Study: Independents save 20-30% without quality loss; implications for value-based care. Takeaway: Subscribe to journals and experiment with AI cautiously.Devices, Tech, and Approvals:Medical AI Warnings: Address biases in GI datasets; great for polyps, risky for diverse monitoring.ESGE on Bariatric Endoscopy: Devices like balloons and duodenal resurfacing—10-15% weight loss, low AEs; await long-term RCTs.New GERD Tools: AFS (EGJ integrity), Milan (manometry), pHoenix (AET), COuGH RefluX (symptoms), Lyon (integrated phenotyping)—revolutionize grading.FDA Approval: SubQ Tremfya for UC: 50% endoscopic response at Week 12; convenient induction sans IV. Takeaway: Train on AI pitfalls and adopt one GERD tool quarterly.Themes & Standouts: Personalization dominates, AI as a tool (not takeover), tech for precision. Revamp gastroparesis care, smart H. pylori screens, and embrace subQ Tremfya.Resources: Links to guidelines, studies, and journals in the episode description. Submit Q&A via app/email. Next up: UEG Week previews!Sponsored by digestivejobs.comhttps://www.gastroendopod.com

This week's episode is packed with breakthrough developments that could reshape gastroenterology practice. We dive deep into the potentially transformative TL1A inhibitors showing remarkable results in IBD, explore the first-ever global consensus guidelines for managing IBD during pregnancy, and discuss how a simple blood test is revolutionizing colorectal cancer screening. Plus, we'll look at cutting-edge capsule technology that could disrupt traditional endoscopy and new research revealing the powerful connection between social factors and gut health.#IBD #CrohnsDisease #UlcerativeColitis #Pregnancy #ColorectalCancer #Screening #Endoscopy #Innovation #Research #Guidelines #TL1A #BloodTest #Capsule #BrainGut #Microbiomehttps://www.gastroendopod.com

🎧 Gastroenterology & Endoscopy Weekly Update | July 30, 2025This week delivered game-changing developments across diagnostics, treatment, and clinical practice. From AI proving its effectiveness in real-world endoscopy to breakthrough therapies for previously "undruggable" cancers, here's what you need to know for your practice.🔬 RESEARCH HIGHLIGHTSAI Endoscopy Meta-Analysis: Comprehensive review of 569 studies shows AI significantly outperforms conventional endoscopy for GI tumor detectionMATTERHORN Trial Results: Imfinzi + chemotherapy reduces disease progression risk by 30% in early gastric/GEJ cancersThailand AI Approval: First country approves AI diagnostic system with 81% accuracy for gastric adenocarcinoma detection💊 FDA & REGULATORY NEWSGeneoscopy ColoSense: Simplified stool collection approved - eliminates scraping requirement, maintains 93% CRC sensitivityImfinzi Priority Review: Breakthrough Therapy designation for first potential perioperative immunotherapy in gastric cancerVS-7375 Fast Track: KRAS G12D inhibitor for pancreatic cancer shows 52% response rate, 100% disease control📋 PRACTICE UPDATESNew ASGE GERD Guidelines: TIF procedures now recommended as PPI alternative for appropriate candidatesEndohepatology Advances: EUS-guided procedures expanding options for liver disease managementAGA Gender Equity Framework: Six-domain approach to addressing workforce diversity challenges⚡ CLINICAL TAKEAWAYS ✅ Prepare for AI-assisted endoscopy integration in your practice ✅ Consider simplified stool tests for screening-resistant patients✅ Implement updated GERD procedural guidelines ✅ Explore endohepatology techniques for cirrhotic patients🎯 KEY STATISTICS44 million Americans aged 45-75 remain unscreened for colorectal cancerEarly gastric cancers missed in 4.5-25.8% of conventional endoscopies100% sensitivity achieved for CRC screening in 45-49 age group with new collection method📚 SOURCES All information compiled from peer-reviewed journals, FDA announcements, and major GI society publications from July 24-30, 2025.⚠️ DISCLAIMER This content is for educational purposes only. Always consult primary sources and official guidelines for clinical decision-making.#Gastroenterology #Endoscopy #AIinMedicine #ColorectalCancer #PancreaticCancer #GERD #ClinicalUpdateshttps://www.gastroendopod.com

In this episode the hosts dive into the latest breakthroughs in gastroenterology and hepatology. From immunotherapy's shift to earlier cancer treatments and new discoveries in IBD, to AI-driven diagnostics and policy impacts on preventive care, the discussion highlights a move toward precise, less invasive, and collaborative patient care. Packed with insights on cancer, liver health, endoscopy, and more, this episode distills key developments without overwhelming the listener.00:00 - Introduction and OverviewWelcome to the podcast and a high-level preview of breakthroughs in gastroenterology, hepatology, cancer treatments, IBD, liver health, and endoscopy techniques. The hosts emphasize pulling out key nuggets for listeners without overload, focusing on shifts toward precise and collaborative care.00:41 - Immunotherapy in Colorectal and Gastric CancerDiscussion on the transformative shift to using immune checkpoint inhibitors earlier in treatment, including perioperative and adjuvant settings for curative intent. Highlights the ATOMIC trial's 50% reduction in recurrence or death for Stage 3 colon cancer patients, challenges in implementation, and the need for multidisciplinary collaboration.01:54 - Early Cancer Detection: Sentinel Polyp and Risk AssessmentExploration of the "sentinel polyp" concept, where a single high-risk polyp (e.g., with high-grade dysplasia) may predict future cancer risk better than polyp count alone. This challenges current surveillance strategies, emphasizing quality over quantity in lesion assessment.02:37 - Germline Mutations in Esophageal AdenocarcinomaFindings that about 9% of esophageal adenocarcinoma patients have inherited mutations, paving the way for personalized genetic screening similar to BRCA testing for breast cancer.02:55 - Inflammatory Bowel Disease (IBD): ETS2 Pathway DiscoveryLandmark identification of the ETS2 pathway as a central driver of inflammation in IBD. Exciting potential for repurposing MEK inhibitors (from oncology) to "turn down" inflammation, ushering in a precision IBD era with tailored treatments based on molecular profiles.03:47 - Liver Health Advances: Aspirin, Cell Therapy, and AIPromising use of low-dose aspirin to reduce liver fat in metabolic dysfunction-associated steatotic liver disease (MASLD). Early results from macrophage cell therapy showing zero liver-related events in advanced cirrhosis patients. Plus, AI's role in hepatocellular carcinoma (HCC) detection, often outperforming human experts on ultrasounds.05:00 - Endoscopy Innovations: Balancing Complexity and Non-InvasivenessDuality in endoscopy: Advanced procedures like endoscopic submucosal tunneling resection for stomach tumors (less invasive than surgery), contrasted with non-invasive tools like the capsule sponge test for Barrett's esophagus to defer procedures in low-risk patients, optimizing resources.05:55 - Health Policy: Supreme Court on Preventive CareU.S. Supreme Court's upholding of the Affordable Care Act's preventive services, ensuring no-cost access to screenings like colorectal cancer tests. Connects policy to clinical innovations, stressing its role in delivering breakthroughs to patients.06:36 - Wrap-Up: Seismic Shifts and Future ImplicationsSummary of the episode's themes, highlighting rapid progress in GI care through science, AI, and collaboration. Poses questions on how data science, policy, and AI will redefine the gastroenterologist's role in a dynamic future.https://www.gastroendopod.com

This week's episode covers the first FDA-approved ingestible gas-sensing capsule, AI-powered endoscopy with spatial computing, promising Crohn's disease therapeutics, and important regulatory updates affecting clinical practice.Revolutionary Diagnostic Technology (00:00 - 01:20)Atmo Biosciences FDA Clearance: First ingestible gas-sensing capsule for gut motility disordersEliminates need for gastric scintigraphy and radio-opaque marker studiesValidated in 209-subject pivotal clinical study across 12 sitesAvailable July 2025AI and Spatial Computing in Endoscopy (01:20 - 02:33)Cosmo Pharmaceuticals + Apple Vision Pro: First clinical study combining AI endoscopy with spatial computingGI Genius AI system integration with Apple Vision Pro headset14.4% increase in adenoma detection ratesStudy begins July 2025 at Rush University Medical Center (Dr. Irving Waxman)Fujifilm EC-860P: New slim colonoscope with enhanced imaging capabilitiesClinical Trial Breakthroughs (02:33 - 03:59)Tulisokibart for Crohn's Disease: APOLLO-CD trial results50% clinical remission vs. 16% historical controlsTL1A protein targeting with precision medicine approachGeneoscopy ColoSense: Real-world screening performance data14% reduction in CRC deaths vs. FIT testing86% reduction vs. blood-based testsRegulatory Updates and Quality Concerns (03:59 - 05:38)FDA Import Alert - Olympus: Restrictions on Aizu facility devicesAffects bronchoscopes, laparoscopes, ureterorenoscopesQuality system violations and compliance issuesNitinotes EndoZip: FDA IDE approval for automated ESG platform184-patient pivotal trial across 10 US sitesProfessional Guidelines and Market Consolidation (05:38 - 06:58)ACG/WGO H. pylori Guidelines: Updated treatment recommendationsEmphasis on clarithromycin resistance testingAGA Crohn's Disease Guidelines: Public comment period through July 20, 2025Torrent-JB Pharmaceuticals: $3.01 billion acquisitionClinical Implications and Future Outlook (06:58 - 08:22)Integration recommendations for clinical practiceConvergence of AI, spatial computing, and precision medicineFuture of gastroenterology practicePublished Research"Tulisokibart for Crohn's Disease: APOLLO-CD Trial Results"The Lancet Gastroenterology & Hepatology50% clinical remission rate in moderate-to-severe Crohn's diseaseCedars-Sinai study led by Dr. Dermot McGovern"ColoSense Real-World Screening Impact Study"Clinical Gastroenterology and Hepatology10-year Markov modeling studySuperior performance vs. FIT and blood-based tests"Atmo Biosciences Gas-Sensing Capsule Validation Study"Pivotal clinical study: 209 subjects across 12 sites (11 US, 1 Australia)FDA 510(k) clearance for gut motility disordersClinical Trials in ProgressCosmo Pharmaceuticals AI + Apple Vision Pro StudyRush University Medical CenterPrincipal Investigator: Dr. Irving WaxmanStudy initiation: July 2025Nitinotes EndoZip Pivotal Trial184 patients across 10 US sitesRandomized controlled trial vs. FDA-approved devicePatient enrollment: Q3 2025https://www.gastroendopod.com

In This Episode, We Cover:Statins as Liver Protectors: A landmark study from Harvard and Mass General reveals that statins can significantly reduce the risk of liver cancer and other complications. The longer you take them, the better the protective benefits.A Palatable New Diet for GI Distress: Researchers at Cedars-Sinai have developed a new elemental diet that patients can actually stick to. This could be a game-changer for individuals with conditions like IBS, SIBO, and Crohn's disease.A Silver Lining for Pancreatitis Patients: A major study shows that GLP-1 receptor agonists, often used for weight loss and diabetes, can dramatically lower the risk of acute pancreatitis in those with chronic pancreatitis.Smarter Crohn's Disease Management: The CURE-CD trial highlights the success of using video capsule endoscopy to guide treatment, leading to fewer flare-ups for high-risk patients.The "Why" Behind the Earlier Colonoscopy Age: Recent data from Kaiser Permanente validates the recommendation to begin colorectal cancer screening at age 45, showing similar rates of concerning polyps and cancer in the 45-49 age group as in the 50-54 group.Journal Watch: A quick look at other important research from early 2025, including advances in esophageal motility disorders, gastroparesis, and celiac disease.Disclaimer: The information in this podcast is for educational purposes only and should not be taken as medical advice. Please consult with your healthcare provider for any personal health concerns.https://www.gastroendopod.com

This episode analyzes pivotal developments in gastroenterology and endoscopy for June 10-16, 2025. The host examines breakthrough IBD therapeutics, revolutionary endoscopic technologies, and updated clinical guidelines that are reshaping practice standards (00:05). Then, we explore cutting-edge AI integration in diagnostic procedures and the clinical implications of new capsule endoscopy advances (02:33). Finally, we discuss the European approval of TREMPFIA as a dual IL-23 inhibitor and evaluate how emerging biosimilars are transforming patient access to specialty care (05:57).Clinical Practice Integration Points:Advanced Endoscopic Technologies - Olympus EZ1500 approval represents significant imaging enhancement with improved depth of field and ergonomic design, while Medtronic's PillCam Genius SB introduces real-time patient alert capabilities that fundamentally change small bowel surveillance protocols.Evidence-Based Guideline Updates - ACG's refined ulcerative colitis management emphasizes personalized diagnostics with prioritized stool testing and systematic disease activity monitoring, while new gastric cancer screening protocols target high-risk populations using the Sydney Protocol framework.Therapeutic Advancement Pipeline - TREMPFIA's dual IL-23 inhibition mechanism for both UC and Crohn's disease, coupled with expanding biosimilar access, represents a paradigm shift in IBD treatment accessibility and clinical outcomes optimization.Key Technical Insights:NaviCam ProScan AI demonstrates measurable efficiency gains in small bowel bleeding detection90%+ bowel preparation adequacy standards now mandatory across all provider networks3-year surveillance intervals established for high-risk gastric conditions requiring systematic biopsy protocolsA big thank you to this week's sponsor:DigestiveJobs.com - Find gastroenterology, hepatology and endoscopy careers worldwide. Post your GI job FREE this month! Visit DigestiveJobs.comhttps://www.gastroendopod.com

Major breakthroughs reshape GI practice this week: AI-assisted colonoscopy proves it can boost adenoma detection rates by 20 percentage points while saving time, the first nutrition diagnostic meets FDA endpoints for IBS management, and new Kaiser data reinforces screening at age 45. Plus, updates on neonatal malabsorption therapy, GI practice consolidation, and the booming OR integration market.🤖 AI Colonoscopy Reaches New MilestoneWorld Journal of Gastroenterology publishes 47-page state-of-the-art reviewCADe platforms increase ADR by average of 20 percentage pointsShortens withdrawal time by 45 secondsAuthors call for cost-effectiveness studies and standardized trainingRead the full review🍽️ Breakthrough IBS Food Test Meets FDA EndpointsBiomerica's inFoods® IBS test achieves primary endpoint in RCT238 patients across 8 U.S. academic centersFDA pain-responder rate: 59.6% vs 42.2% (placebo diet)Strongest efficacy in IBS-M: 66% respondersFirst nutrition diagnostic to meet prespecified IBS endpointsPublished in Gastroenterology    🏥 Practice Consolidation UpdateDignity Health acquires Sierra Nevada GastroenterologyGrass Valley, CA clinic closes June 9, reopens June 16Includes endoscopy suite upgrades and EPIC integrationReflects ongoing health system consolidation trend👶 First Neonatal Malabsorption Drug Trial BeginsElgan Pharma & Chiesi launch Phase 3 NEOMAL studyELGN-2112 for very-low-birth-weight neonates (n≈240)Primary endpoint: weight-for-age z-score at 6 weeksCould become first pharmacologic therapy for condition📊 CRC Screening at 45 ValidatedKaiser Northern California cohort study in JAMA25,000 patients comparing ages 45-49 vs 50-54Similar rates of advanced adenoma, serrated lesions, CRCOnly difference: adenoma prevalence (35.4% vs 40.8%)Reinforces USPSTF/ACS guidelines💻 OR Integration Market ForecastMarket projected to reach $6.9 billion by 20315% CAGR driven by 4K imaging, cloud routing, hybrid suitesHospitals bundling AI-ready colonoscopy platformsCapital planning implications for 2026Key TakeawaysAI in colonoscopy is ready for prime time - but needs proper implementationPersonalized nutrition arrives for IBS - test-guided diets outperform placeboAge 45 screening is evidence-based - update your protocols nowConsolidation continues - independent groups need strategic planningTech investment is mandatory - 4K and AI capabilities becoming standardResources & ReferencesAI Colonoscopy Review (World J Gastroenterol 2025)inFoods® IBS RCT (Gastroenterology June 2025)Kaiser CRC Screening Study (JAMA June 2025)iData OR Integration Market Report (June 2025)NEOMAL Trial Registration (ClinicalTrials.gov)Episode SponsorDigestiveJobs.com - Find gastroenterology, hepatology and endoscopy careers worldwide. Post your GI job FREE this month! Visit DigestiveJobs.comDisclaimerThis podcast provides educational content for healthcare professionals. Information should not replace clinical judgment. Consult primary sources and guidelines for patient care decisions.https://www.gastroendopod.com